Recent Posts



CDC and FDA Agree To Resume Johnson & Johnson COVID-19 Vaccine

On Friday, the US Centers for Disease Control and Prevention and Food and Drug Administration lifted their recommended pause on the use of Johnson & Johnson's coronavirus vaccine. This time the vaccine will have a warning label that warns users about blood clot risks.

According to CBS News, a total of three women have died from the clotting disorder after receiving the Janssen vaccine, out of 16 cases like it in total among women in the U.S. Seven remain hospitalized and five have been released. Most were under the age of 50.

A panel of advisers to the Centers for Disease Control and Prevention voted on Friday to recommend resuming the Johnson & Johnson vaccine.

"We have concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older," acting FDA Commissioner Dr. Janet Woodcock said in a statement.

“We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality. We recommend people with questions about which vaccine is right for them have those discussions with their health care provider."

"I support the ACIP's recommendation that the Johnson and Johnson COVID-19 vaccine be used for persons 18 years of age or older in the United States population under the FDA emergency use authorization, and I have signed this recommendation," CDC Director Dr. Rochelle Walensky said Friday.

"With these actions, the administration of Johnson and Johnson's COVID-19 vaccine can resume immediately."

Vaccinations could resume as soon as Saturday, the FDA said